These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 32947972)

  • 1. NASH, Fibrosis and Hepatocellular Carcinoma: Lipid Synthesis and Glutamine/Acetate Signaling.
    Sunami Y
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32947972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients.
    Chiappini F; Coilly A; Kadar H; Gual P; Tran A; Desterke C; Samuel D; Duclos-Vallée JC; Touboul D; Bertrand-Michel J; Brunelle A; Guettier C; Le Naour F
    Sci Rep; 2017 Apr; 7():46658. PubMed ID: 28436449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
    Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
    Kutlu O; Kaleli HN; Ozer E
    Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease.
    Bhat N; Mani A
    Nutrients; 2023 May; 15(10):. PubMed ID: 37242206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators.
    Piccinin E; Villani G; Moschetta A
    Nat Rev Gastroenterol Hepatol; 2019 Mar; 16(3):160-174. PubMed ID: 30518830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPARC inhibition accelerates NAFLD-associated hepatocellular carcinoma development by dysregulating hepatic lipid metabolism.
    M Onorato A; Fiore E; Bayo J; Casali C; Fernandez-Tomé M; Rodríguez M; Domínguez L; Argemi J; Hidalgo F; Favre C; García M; Atorrasagasti C; Mazzolini GD
    Liver Int; 2021 Jul; 41(7):1677-1693. PubMed ID: 33641248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis and non-alcoholic fatty liver diseases.
    Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
    World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteome Characteristics of Non-Alcoholic Steatohepatitis Liver Tissue and Associated Hepatocellular Carcinomas.
    Kakehashi A; Stefanov VE; Ishii N; Okuno T; Fujii H; Kawai K; Kawada N; Wanibuchi H
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28218651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.
    Agosti P; Sabbà C; Mazzocca A
    Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):607-617. PubMed ID: 29197664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXK1 promotes nonalcoholic fatty liver disease by mediating mTORC1-dependent inhibition of hepatic fatty acid oxidation.
    Fujinuma S; Nakatsumi H; Shimizu H; Sugiyama S; Harada A; Goya T; Tanaka M; Kohjima M; Takahashi M; Izumi Y; Yagi M; Kang D; Kaneko M; Shigeta M; Bamba T; Ohkawa Y; Nakayama KI
    Cell Rep; 2023 May; 42(5):112530. PubMed ID: 37209098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies.
    Wang GY; Zhang XY; Wang CJ; Guan YF
    World J Gastroenterol; 2023 Jan; 29(1):75-95. PubMed ID: 36683713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
    Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
    Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis.
    Branković M; Jovanović I; Dukić M; Radonjić T; Oprić S; Klašnja S; Zdravković M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.
    Oniciu DC; Hashiguchi T; Shibazaki Y; Bisgaier CL
    PLoS One; 2018; 13(5):e0194568. PubMed ID: 29847555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.